{"id":78732,"date":"2024-07-09T11:58:00","date_gmt":"2024-07-09T11:58:00","guid":{"rendered":"https:\/\/www.cofb.org\/?p=78732"},"modified":"2024-07-09T12:30:53","modified_gmt":"2024-07-09T12:30:53","slug":"prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/ca\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/","title":{"rendered":"Prop de 100 farmac\u00e8utics i farmac\u00e8utiques d’hospitals aprofundeixen\u00a0en els c\u00e0ncers ginecol\u00f2gics"},"content":{"rendered":"\n

Els passats mesos de maig i juny, el Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) <\/strong>va organitzar, amb la col\u00b7laboraci\u00f3 de la Societat Catalana de Farm\u00e0cia Cl\u00ednica (SCFC)<\/a> <\/strong>la formaci\u00f3 \u201cActualitzaci\u00f3 en c\u00e0ncers ginecol\u00f2gics\u201d<\/strong>, amb el patrocini d\u2019AstraZeneca<\/a>. Les sessions, adre\u00e7ades a farmac\u00e8utics i farmac\u00e8utiques d\u2019hospital<\/strong>, va ser coordinada pel vocal d\u2019Hospitals del COFB, David Conde<\/strong>, i impartida per Cristina Martin<\/strong>, onc\u00f2loga adjunta del Servei d\u2019Oncologia M\u00e8dica de la divisi\u00f3 de c\u00e0ncer urol\u00f2gic i ginecol\u00f2gic de l\u2019Hospital de la Santa Creu i Sant Pau; \u00c1lvaro Taus<\/strong>, onc\u00f2leg adjunt del Servei d\u2019Oncologia M\u00e8dica de la divisi\u00f3 de c\u00e0ncer ginecol\u00f2gic i de pulm\u00f3 de l\u2019Hospital del Mar; Julen Fern\u00e1ndez<\/strong>, onc\u00f2leg adjunt del Servei d\u2019Oncologia M\u00e8dica de la divisi\u00f3 de c\u00e0ncer ginecol\u00f2gic i gastrointestinal de l\u2019Hospital Universitari M\u00fatua de Terrassa; i Milana Bergamino<\/strong>, onc\u00f2loga adjunta de la divisi\u00f3 de c\u00e0ncer de mama de l\u2019Institut Catal\u00e0 d\u2019Oncologia (ICO) de Badalona.<\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

L\u2019objectiu de la formaci\u00f3, que va tenir lloc els dies 30 de maig i 6, 13 i 20 de juny, van ser revisar la fisiopatologia dels diferents c\u00e0ncers ginecol\u00f2gics<\/strong>, actualitzar la gesti\u00f3 <\/strong>i el tractament<\/strong> d\u2019aquests c\u00e0ncers, presentar les perspectives de futur<\/strong> i revisar els aspectes relacionats amb l\u2019atenci\u00f3 farmac\u00e8utica<\/strong> en la dispensaci\u00f3 de tractaments per combatre aquests tipus de tumors.<\/strong><\/p>\n\n\n\n

La formaci\u00f3, amb prop de 100 farmac\u00e8utics i farmac\u00e8utiques participants<\/strong>, va compaginar sessions te\u00f2riques amb casos pr\u00e0ctics en qu\u00e8 es va profunditzar en l\u2019actualitzaci\u00f3 en el tractament i pron\u00f2stic del c\u00e0ncer d\u2019ovari, de c\u00e8rvix, d\u2019endometri i en c\u00e0ncer de mama<\/strong>. \u201cAquesta formaci\u00f3 dona resposta a la necessitat d\u2019actualitzaci\u00f3 d\u2019aquests tumors<\/strong>, en relaci\u00f3 amb les grans novetats<\/strong> que han arribat pel que fa a l\u2019arsenal terap\u00e8utic per combatre\u2019ls<\/strong>\u201d, va indicar el vocal d\u2019Hospitals del COFB, David Conde<\/strong>.<\/p>\n\n\n\n

\"El<\/a>
El vocal d’Hospitals del COFB, David Conde, presentant la formaci\u00f3 “Actualitzaci\u00f3 en c\u00e0ncers ginecol\u00f2gics”.<\/figcaption><\/figure>\n\n\n\n

C\u00e0ncer d\u2019ovari<\/strong><\/h2>\n\n\n\n

Al llarg de la primera sessi\u00f3, celebrada el 30 de maig, Cristina Martin<\/strong>, onc\u00f2loga adjunta del Servei d\u2019Oncologia M\u00e8dica de l\u2019Hospital de la Santa Creu i Sant Pau va abordar el c\u00e0ncer d\u2019ovari<\/strong>, que \u201ccontinua sent el c\u00e0ncer ginecol\u00f2gic m\u00e9s letal<\/strong>\u201d. Per aquesta ra\u00f3, l\u2019onc\u00f2loga va apuntar que cal millorar els m\u00e8todes de cribratge<\/strong> i els tractaments de primera l\u00ednia <\/strong>per curar els pacients.<\/p>\n\n\n\n

\"Cristina<\/a>
Cristina Martin en un moment de la seva exposici\u00f3. <\/figcaption><\/figure>\n\n\n\n

L\u2019onc\u00f2loga va explicar que, en els darrers anys, hi ha hagut un canvi de paradigma<\/strong> que pot ajudar a personalitzar el tractament<\/strong>, tant pel que fa al diagn\u00f2stic com al tractament del c\u00e0ncer d\u2019ovari. En aquest sentit, va exposar quines s\u00f3n les dianes terap\u00e8utiques actuals<\/strong>, sobretot pel que fa al tractament en primera l\u00ednia per al c\u00e0ncer d\u2019ovari avan\u00e7at. Tanmateix, va fer refer\u00e8ncia a les novetats dels tractaments en segona l\u00ednia<\/strong>; a la cirurgia<\/strong>, que \u201c\u00e9s clau per impactar en la superviv\u00e8ncia\u201d; i la immunoter\u00e0pia<\/strong>, que \u201c\u00e9s el futur\u201d<\/strong>.<\/p>\n\n\n\n

C\u00e0ncer de c\u00e8rvix<\/strong><\/h2>\n\n\n\n

En la seg\u00fcent sessi\u00f3, que va tenir lloc el 6 de juny, va intervenir l\u2019onc\u00f2leg adjunt del Servei d\u2019Oncologia M\u00e8dica de la divisi\u00f3 de c\u00e0ncer ginecol\u00f2gic i de pulm\u00f3 de l\u2019Hospital del Mar, \u00c1lvaro Taus<\/strong>, per parlar sobre el c\u00e0ncer de c\u00e8rvix<\/strong>, \u201cla principal causa de mort per c\u00e0ncer a l\u2019\u00c0frica i a l\u2019Am\u00e8rica Llatina<\/strong>\u201d. L\u2019onc\u00f2leg va especificar que, en la majoria dels casos de c\u00e0ncer de c\u00e8rvix, la causa principal <\/strong>\u00e9s la infecci\u00f3 cr\u00f2nica del Virus del Papil\u00b7loma Hum\u00e0 (VPH). <\/strong>Per aquesta ra\u00f3, va assegurar que \u00e9s molt important la prevenci\u00f3<\/strong>, mitjan\u00e7ant la vacunaci\u00f3 del VPH <\/strong>i els programes de cribratge<\/strong>, per assolir l\u2019objectiu mundial<\/strong> marcat per l\u2019Organitzaci\u00f3 Mundial de la Salut (OMS).<\/strong><\/p>\n\n\n\n

\"\u00c1lvaro<\/a>
\u00c1lvaro Taus durant la seva intervenci\u00f3. <\/figcaption><\/figure>\n\n\n\n

Al llarg de la formaci\u00f3 sobre el c\u00e0ncer de c\u00e8rvix, \u00c1lvaro Taus, va repassar l\u2019arsenal terap\u00e8utic<\/strong> per combatre aquest tipus de c\u00e0ncer. En c\u00e0ncers de c\u00e8rvix, localment avan\u00e7ats, \u201cel tractament \u00e9s la combinaci\u00f3 de quimioter\u00e0pia\u201d, va indicar. Alhora, va compartir que, recentment, s\u2019ha demostrat que la combinaci\u00f3 amb immunoter\u00e0pia, com el pembrolizumab a la quimioter\u00e0pia, comporta m\u00e9s superviv\u00e8ncia lliure de progressi\u00f3 (SLP). Aix\u00ed mateix, el doctor va detallar els tractaments en primera i segona l\u00ednia i les novetats m\u00e9s recents per combatre aquest c\u00e0ncer.<\/p>\n\n\n\n

C\u00e0ncer d\u2019endometri<\/strong><\/h2>\n\n\n\n

Per la seva banda, Julen Fern\u00e1ndez<\/strong>, onc\u00f2leg adjunt del Servei d\u2019Oncologia M\u00e8dica de la divisi\u00f3 de c\u00e0ncer ginecol\u00f2gic i gastrointestinal de l\u2019Hospital Universitari M\u00fatua de Terrassa, va abordar el c\u00e0ncer d\u2019endometri<\/strong> al llarg de la tercera sessi\u00f3, que va tenir lloc el 13 de juny. Es tracta del \u201ctumor ginecol\u00f2gic m\u00e9s freq\u00fcent en pa\u00efsos desenvolupats\u201d<\/strong>, segons va apuntar.<\/p>\n\n\n\n

\"\"<\/a>
Julen Fern\u00e1ndez en un moment de la presentaci\u00f3. <\/figcaption><\/figure>\n\n\n\n

L\u2019onc\u00f2leg va exposar l\u2019arsenal terap\u00e8utic <\/strong>per combatre aquest tumor. En aquest sentit, va explicar que en la majoria dels diagn\u00f2stics en estadi I<\/strong>, la cirurgia <\/strong>\u00e9s l\u2019elecci\u00f3 i pot curar la malaltia. Tamb\u00e9 va fer refer\u00e8ncia al paper del gangli sentinella<\/strong> per prioritzar o no la cirurgia de ganglis i va profunditzar en el tractament en primera l\u00ednia<\/strong>.<\/p>\n\n\n\n

Adjuv\u00e0ncia en c\u00e0ncer de mama<\/strong><\/h2>\n\n\n\n

Finalment, en la darrera sessi\u00f3 formativa celebrada el 20 de juny, l\u2019onc\u00f2loga adjunta de la divisi\u00f3 de c\u00e0ncer de mama de l\u2019Institut Catal\u00e0 d\u2019Oncologia (ICO) de Badalona, Milana Bergamino<\/strong>, va tractar l\u2019adjuv\u00e0ncia en c\u00e0ncer de mama<\/strong>. \u201cEl c\u00e0ncer de mama \u00e9s la primera causa de major p\u00e8rdua de qualitat de vida en dones\u201d, va assegurar Bergamino. L\u2019onc\u00f2loga va fer esment del fet que hi ha molts factors de risc<\/strong>, tot i que \u201ces desconeix el pes espec\u00edfic de cadascun d\u2019ells\u201d<\/strong>.<\/p>\n\n\n\n

\"Milana<\/a>
Milana Bergamino en la seva intervenci\u00f3 sobre c\u00e0ncer de mama. <\/figcaption><\/figure>\n\n\n\n

Al llarg de la seva exposici\u00f3, Bergamino es va centrar en el tractament adjuvant pel c\u00e0ncer de mama<\/strong>, que s\u2019ha de realitzar en tumors HER2 positius, triples negatius i tumors d\u2019alta proliferaci\u00f3.<\/p>\n\n\n\n

<\/div>
\n
<\/div><\/div>\n\n\n\n
<\/div><\/div>\n\n\n\n
<\/div>\n

Amb la col\u00b7laboraci\u00f3 de:<\/strong><\/p>\n\n\n\n

\"\"<\/a><\/figure>\n<\/div>\n<\/div><\/section>\n\n\n\n
<\/div>
\n
<\/div><\/div>\n\n\n\n
<\/div><\/div>\n\n\n\n
<\/div>\n

Amb el patrocini de:<\/strong><\/strong><\/p>\n\n\n\n

\"\"<\/a><\/figure>\n<\/div>\n<\/div><\/section>\n","protected":false},"excerpt":{"rendered":"

Els passats mesos de maig i juny, el Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) va organitzar, amb la col\u00b7laboraci\u00f3 de la Societat Catalana de Farm\u00e0cia Cl\u00ednica (SCFC) la formaci\u00f3 \u201cActualitzaci\u00f3 en c\u00e0ncers ginecol\u00f2gics\u201d, amb el patrocini d\u2019AstraZeneca. Les sessions, adre\u00e7ades a farmac\u00e8utics i farmac\u00e8utiques d\u2019hospital, va ser coordinada pel vocal […]<\/p>\n","protected":false},"author":3,"featured_media":78748,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[23,57],"tags":[5062,723,5058,5055,5054,4997,753,5059,5056,5057,5050,5051,18,19,53,1038,5053,5052,68,70,5060,63,5061,484],"class_list":["post-78732","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-destacats","category-mon-collegial","tag-arsenal-terapeutic","tag-cancer","tag-cancer-cervix","tag-cancer-dendometri","tag-cancer-dovari","tag-cancer-de-cervix","tag-cancer-de-mama","tag-cancer-endometri","tag-cancer-mama","tag-cancer-ovari","tag-cancers","tag-cancers-ginecologics","tag-cofb","tag-collegi-de-farmaceutics-de-barcelona","tag-farmaceutics","tag-farmaceutics-hospital","tag-farmaceutiques-hospital","tag-farmaceutiques-hospitalaries","tag-farmacia","tag-formacio","tag-pronostic","tag-tractament","tag-tumors","tag-vocalia-dhospitals"],"yoast_head":"\nProp de 100 farmac\u00e8utics i farmac\u00e8utiques d'hospitals aprofundeixen\u00a0en els c\u00e0ncers ginecol\u00f2gics - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"description\" content=\"Els passat mesos de maig i juny, el COFB va organitzar, amb la col\u00b7laboraci\u00f3 de la SCFC la formaci\u00f3 \u201cActualitzaci\u00f3 en c\u00e0ncers ginecol\u00f2gics\u201d.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cofb.org\/ca\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prop de 100 farmac\u00e8utics i farmac\u00e8utiques d'hospitals aprofundeixen\u00a0en els c\u00e0ncers ginecol\u00f2gics - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Els passat mesos de maig i juny, el COFB va organitzar, amb la col\u00b7laboraci\u00f3 de la SCFC la formaci\u00f3 \u201cActualitzaci\u00f3 en c\u00e0ncers ginecol\u00f2gics\u201d.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cofb.org\/ca\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-09T11:58:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-09T12:30:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1407\" \/>\n\t<meta property=\"og:image:height\" content=\"939\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Berta Mart\u00ednez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Berta Mart\u00ednez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/\"},\"author\":{\"name\":\"Berta Mart\u00ednez\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/f32de3b41b812c85ff923cb4cc849063\"},\"headline\":\"Prop de 100 farmac\u00e8utics i farmac\u00e8utiques d’hospitals aprofundeixen\u00a0en els c\u00e0ncers ginecol\u00f2gics\",\"datePublished\":\"2024-07-09T11:58:00+00:00\",\"dateModified\":\"2024-07-09T12:30:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/\"},\"wordCount\":1118,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg\",\"keywords\":[\"arsenal terap\u00e8utic\",\"c\u00e0ncer\",\"c\u00e0ncer c\u00e8rvix\",\"c\u00e0ncer d'endometri\",\"c\u00e0ncer d'ovari\",\"c\u00e0ncer de c\u00e8rvix\",\"c\u00e0ncer de mama\",\"c\u00e0ncer endometri\",\"c\u00e0ncer mama\",\"c\u00e0ncer ovari\",\"c\u00e0ncers\",\"c\u00e0ncers ginecol\u00f2gics\",\"COFB\",\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"farmac\u00e8utics\",\"farmac\u00e8utics hospital\",\"farmac\u00e8utiques hospital\",\"farmac\u00e8utiques hospital\u00e0ries\",\"Farm\u00e0cia\",\"Formaci\u00f3\",\"pron\u00f2stic\",\"tractament\",\"tumors\",\"Vocalia d'Hospitals\"],\"articleSection\":[\"Destacats\",\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/\",\"url\":\"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/\",\"name\":\"Prop de 100 farmac\u00e8utics i farmac\u00e8utiques d'hospitals aprofundeixen\u00a0en els c\u00e0ncers ginecol\u00f2gics - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg\",\"datePublished\":\"2024-07-09T11:58:00+00:00\",\"dateModified\":\"2024-07-09T12:30:53+00:00\",\"description\":\"Els passat mesos de maig i juny, el COFB va organitzar, amb la col\u00b7laboraci\u00f3 de la SCFC la formaci\u00f3 \u201cActualitzaci\u00f3 en c\u00e0ncers ginecol\u00f2gics\u201d.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#primaryimage\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg\",\"width\":1407,\"height\":939},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prop de 100 farmac\u00e8utics i farmac\u00e8utiques d’hospitals aprofundeixen\u00a0en els c\u00e0ncers ginecol\u00f2gics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/f32de3b41b812c85ff923cb4cc849063\",\"name\":\"Berta Mart\u00ednez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d4c584dab5da1ee9e3c3df161c0aabec7075cc8211cd46ffc79bfe177aa78b01?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d4c584dab5da1ee9e3c3df161c0aabec7075cc8211cd46ffc79bfe177aa78b01?s=96&d=mm&r=g\",\"caption\":\"Berta Mart\u00ednez\"},\"url\":\"https:\/\/www.cofb.org\/ca\/author\/bmartinez\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prop de 100 farmac\u00e8utics i farmac\u00e8utiques d'hospitals aprofundeixen\u00a0en els c\u00e0ncers ginecol\u00f2gics - Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"Els passat mesos de maig i juny, el COFB va organitzar, amb la col\u00b7laboraci\u00f3 de la SCFC la formaci\u00f3 \u201cActualitzaci\u00f3 en c\u00e0ncers ginecol\u00f2gics\u201d.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cofb.org\/ca\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/","og_locale":"ca_ES","og_type":"article","og_title":"Prop de 100 farmac\u00e8utics i farmac\u00e8utiques d'hospitals aprofundeixen\u00a0en els c\u00e0ncers ginecol\u00f2gics - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"Els passat mesos de maig i juny, el COFB va organitzar, amb la col\u00b7laboraci\u00f3 de la SCFC la formaci\u00f3 \u201cActualitzaci\u00f3 en c\u00e0ncers ginecol\u00f2gics\u201d.","og_url":"https:\/\/www.cofb.org\/ca\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2024-07-09T11:58:00+00:00","article_modified_time":"2024-07-09T12:30:53+00:00","og_image":[{"width":1407,"height":939,"url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg","type":"image\/jpeg"}],"author":"Berta Mart\u00ednez","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrit per":"Berta Mart\u00ednez","Temps estimat de lectura":"7 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#article","isPartOf":{"@id":"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/"},"author":{"name":"Berta Mart\u00ednez","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/f32de3b41b812c85ff923cb4cc849063"},"headline":"Prop de 100 farmac\u00e8utics i farmac\u00e8utiques d’hospitals aprofundeixen\u00a0en els c\u00e0ncers ginecol\u00f2gics","datePublished":"2024-07-09T11:58:00+00:00","dateModified":"2024-07-09T12:30:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/"},"wordCount":1118,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg","keywords":["arsenal terap\u00e8utic","c\u00e0ncer","c\u00e0ncer c\u00e8rvix","c\u00e0ncer d'endometri","c\u00e0ncer d'ovari","c\u00e0ncer de c\u00e8rvix","c\u00e0ncer de mama","c\u00e0ncer endometri","c\u00e0ncer mama","c\u00e0ncer ovari","c\u00e0ncers","c\u00e0ncers ginecol\u00f2gics","COFB","Col\u00b7legi de Farmac\u00e8utics de Barcelona","farmac\u00e8utics","farmac\u00e8utics hospital","farmac\u00e8utiques hospital","farmac\u00e8utiques hospital\u00e0ries","Farm\u00e0cia","Formaci\u00f3","pron\u00f2stic","tractament","tumors","Vocalia d'Hospitals"],"articleSection":["Destacats","M\u00f3n col\u00b7legial"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/","url":"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/","name":"Prop de 100 farmac\u00e8utics i farmac\u00e8utiques d'hospitals aprofundeixen\u00a0en els c\u00e0ncers ginecol\u00f2gics - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#primaryimage"},"image":{"@id":"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg","datePublished":"2024-07-09T11:58:00+00:00","dateModified":"2024-07-09T12:30:53+00:00","description":"Els passat mesos de maig i juny, el COFB va organitzar, amb la col\u00b7laboraci\u00f3 de la SCFC la formaci\u00f3 \u201cActualitzaci\u00f3 en c\u00e0ncers ginecol\u00f2gics\u201d.","breadcrumb":{"@id":"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#primaryimage","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg","width":1407,"height":939},{"@type":"BreadcrumbList","@id":"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Prop de 100 farmac\u00e8utics i farmac\u00e8utiques d’hospitals aprofundeixen\u00a0en els c\u00e0ncers ginecol\u00f2gics"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/f32de3b41b812c85ff923cb4cc849063","name":"Berta Mart\u00ednez","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d4c584dab5da1ee9e3c3df161c0aabec7075cc8211cd46ffc79bfe177aa78b01?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d4c584dab5da1ee9e3c3df161c0aabec7075cc8211cd46ffc79bfe177aa78b01?s=96&d=mm&r=g","caption":"Berta Mart\u00ednez"},"url":"https:\/\/www.cofb.org\/ca\/author\/bmartinez\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg",1407,939,false],"thumbnail":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0-150x150.jpg",150,150,true],"medium":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0-300x200.jpg",300,200,true],"medium_large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0-768x513.jpg",768,513,true],"large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0-1024x683.jpg",1024,683,true],"1536x1536":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg",1407,939,false],"2048x2048":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg",1407,939,false],"trp-custom-language-flag":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0-18x12.jpg",18,12,true]},"uagb_author_info":{"display_name":"Berta Mart\u00ednez","author_link":"https:\/\/www.cofb.org\/ca\/author\/bmartinez\/"},"uagb_comment_info":0,"uagb_excerpt":"Els passats mesos de maig i juny, el Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) va organitzar, amb la col\u00b7laboraci\u00f3 de la Societat Catalana de Farm\u00e0cia Cl\u00ednica (SCFC) la formaci\u00f3 \u201cActualitzaci\u00f3 en c\u00e0ncers ginecol\u00f2gics\u201d, amb el patrocini d\u2019AstraZeneca. Les sessions, adre\u00e7ades a farmac\u00e8utics i farmac\u00e8utiques d\u2019hospital, va ser coordinada pel vocal […]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/78732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/comments?post=78732"}],"version-history":[{"count":47,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/78732\/revisions"}],"predecessor-version":[{"id":78802,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/78732\/revisions\/78802"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media\/78748"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media?parent=78732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/categories?post=78732"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/tags?post=78732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}